![](/images/graphics-bg.png)
The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience
المؤلفون المشاركون
Enns, Robert
Bressler, Brian
Mitchell, Robert A.
Shuster, Constantin
DeMarco, Mari L.
Rosenfeld, Gregory
Galorport, Cherry
Shahidi, Neal
المصدر
Canadian Journal of Gastroenterology and Hepatology
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-11-10
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Background.
Infliximab (IFX) therapeutic drug monitoring (TDM) allows for objective decision making in patients with inflammatory bowel disease (IBD) and loss of response.
Questions remain about whether IFX TDM improves outcomes.
Methods.
Patients with IBD who had IFX TDM due to concerns for loss of response were considered for inclusion.
Serum IFX trough concentration and anti-drug antibody (ADA) concentrations were measured.
Patients were grouped by TDM results: group 1, low IFX/high ADA; group 2, low IFX/low ADA; group 3, therapeutic IFX.
Changes in management were analyzed according to groupings; remission rates were assessed at 6 months.
Results.
71 patients were included of whom 37% underwent an appropriate change in therapy.
Groups 1 (67%) and 2 (83%) had high adherence compared to only 9% in group 3.
At 6 months, 57% had achieved remission.
More patients who underwent an appropriate change in therapy achieved remission, though this did not reach statistical significance (69% versus 49%; P=0.098).
Conclusions.
A trend towards increased remission rates was associated with appropriate changes in management following TDM results.
Many patients with therapeutic IFX concentrations did not undergo an appropriate change in management, potentially reflecting a lack of available out-of-class options at the time of TDM or due to uncertainty of the meaning of the reported therapeutic range.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Mitchell, Robert A.& Shuster, Constantin& Shahidi, Neal& Galorport, Cherry& DeMarco, Mari L.& Rosenfeld, Gregory…[et al.]. 2016. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience. Canadian Journal of Gastroenterology and Hepatology،Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1099884
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Mitchell, Robert A.…[et al.]. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience. Canadian Journal of Gastroenterology and Hepatology No. 2016 (2016), pp.1-7.
https://search.emarefa.net/detail/BIM-1099884
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Mitchell, Robert A.& Shuster, Constantin& Shahidi, Neal& Galorport, Cherry& DeMarco, Mari L.& Rosenfeld, Gregory…[et al.]. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience. Canadian Journal of Gastroenterology and Hepatology. 2016. Vol. 2016, no. 2016, pp.1-7.
https://search.emarefa.net/detail/BIM-1099884
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1099884
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)